ISPOR - Utilization, Reimbursement, and Price of Incretin-Based and Peptides Therapies for Type 2 Diabetes in US Medicaid Program from 2005 to 2016

Full Text

Utilization, Reimbursement, and Price of Incretin-Based and Peptides Therapies for Type 2 Diabetes in US Medicaid Program from 2005 to 2016

Abstract

Authors

ZM Almarhoon N Messinger JJ Guo

Back to Volume 21, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now